Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Afqlir is the preferred biosimilar brand of aflibercept. All new patients should only be initiated on Afqlir.
- Originator – Eylea
- Biosimilar – Afqlir
Aflibercept 30.1mg/263microlitres (Eylea HD/Eylea 8mg) is indicated for neovascular (wet) Age-related Macular Hegeneration (nAMD) and Diabetic Macular Oedema (DMO) ONLY
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection |
Where more than one biologic treatment is suitable, it is the responsibility of the provider to ensure the most cost-effective option is selected.
Biosimilars are available which should be used in line with local contracting agreements.
Originator - Lecentis
Biosimilars - Byooviz
; Ongavia ; Ranivisio; Rimmyrah ; Ximluci
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
Bevacizumab gamma is recommended as an option for treating wet age-related macular degeneration in adults (as per NICE TA1022), only if:
-
the eye has a best-corrected visual acuity between 6/12 and 6/96
-
there is no permanent structural damage to the central fovea
-
the lesion size is 12 disc areas or less in greatest linear dimension
-
there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)
| Pack |
|---|
| 1 vial |